| Debra Bell Garber, MA CCC-A | |
|
8780 W Golf Rd, Suite 200, Niles, IL 60714-5602 | |
| (847) 824-4390 | |
| (847) 824-1712 |
| Full Name | Debra Bell Garber |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 41 Years |
| Location | 8780 W Golf Rd, Niles, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477768075 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 147000410 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ear Nose Throat And Allergy Clinic, S.c. | 8224134689 | 2 |
News Archive
A study from the University of Gothenburg, Sweden, shows that the drop in boys' physical activity during the teenage years levels off in early adulthood.
Patients with Parkinson's disease have deceases in functional connectivity over time and these correlate closely with cognitive decline, research shows.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 5 days ago
| Provider Name | Ear Nose & Throat Specialists Of Illinois Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1750340949 PECOS PAC ID: 7911970389 Enrollment ID: O20040813001041 |
News Archive
A study from the University of Gothenburg, Sweden, shows that the drop in boys' physical activity during the teenage years levels off in early adulthood.
Patients with Parkinson's disease have deceases in functional connectivity over time and these correlate closely with cognitive decline, research shows.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 5 days ago
| Provider Name | Naperville Ear, Nose And Throat Associates., Ltd. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1205875119 PECOS PAC ID: 9830124544 Enrollment ID: O20050930000771 |
News Archive
A study from the University of Gothenburg, Sweden, shows that the drop in boys' physical activity during the teenage years levels off in early adulthood.
Patients with Parkinson's disease have deceases in functional connectivity over time and these correlate closely with cognitive decline, research shows.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 5 days ago
| Provider Name | North Side Audiology Group, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053442491 PECOS PAC ID: 0547283491 Enrollment ID: O20060106000379 |
News Archive
A study from the University of Gothenburg, Sweden, shows that the drop in boys' physical activity during the teenage years levels off in early adulthood.
Patients with Parkinson's disease have deceases in functional connectivity over time and these correlate closely with cognitive decline, research shows.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 5 days ago
| Provider Name | Ear Nose Throat And Allergy Clinic, S.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1942341961 PECOS PAC ID: 8224134689 Enrollment ID: O20070501000241 |
News Archive
A study from the University of Gothenburg, Sweden, shows that the drop in boys' physical activity during the teenage years levels off in early adulthood.
Patients with Parkinson's disease have deceases in functional connectivity over time and these correlate closely with cognitive decline, research shows.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Debra Bell Garber, MA CCC-A 8780 W Golf Rd, Suite 200, Niles, IL 60714-5602 Ph: (847) 824-4390 | Debra Bell Garber, MA CCC-A 8780 W Golf Rd, Suite 200, Niles, IL 60714-5602 Ph: (847) 824-4390 |
News Archive
A study from the University of Gothenburg, Sweden, shows that the drop in boys' physical activity during the teenage years levels off in early adulthood.
Patients with Parkinson's disease have deceases in functional connectivity over time and these correlate closely with cognitive decline, research shows.
Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 5 days ago
Hearing Professionals Of Illinois Audiologist Medicare: Not Enrolled in Medicare Practice Location: 8780 Golf Rd, Suite 200, Niles, IL 60714 Phone: 847-824-4390 Fax: 847-824-1712 | |
Dr. Phyllis Stern-weisman, AUD, CCC-A, FAAA Audiologist Medicare: Accepting Medicare Assignments Practice Location: 7638 N Milwaukee Ave, Niles, IL 60714 Phone: 847-966-0060 Fax: 847-966-2046 | |
Lauren Olivia Kelly, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 8780 W Golf Rd Ste 200, Niles, IL 60714 Phone: 847-824-4390 | |
Jeanmarie Carone, M.A. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 8780 W Golf Rd, Niles, IL 60714 Phone: 847-824-8799 | |
Mary Ann Jordan, Audiologist Medicare: Accepting Medicare Assignments Practice Location: 8780 W Golf Rd, Suite 200, Niles, IL 60714 Phone: 847-824-1712 | |
Mrs. Sheri Yamashita Van Gelderen, M.A., CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 8780 W Golf Rd, Suite 200, Niles, IL 60714 Phone: 847-824-4390 Fax: 847-824-1712 |